Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity.
about
Bacterial Cytosine Deaminase Mutants Created by Molecular Engineering Show Improved 5-Fluorocytosine-Mediated Cell Killing In vitro and In vivoSuccessful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide librariesFusion enzymes containing HSV-1 thymidine kinase mutants and guanylate kinase enhance prodrug sensitivity in vitro and in vivo.Advances in preclinical investigation of prostate cancer gene therapy.Engineering Kinases to Phosphorylate Nucleoside Analogs for Antiviral and Cancer Therapy.Prodrug activation by Cryptosporidium thymidine kinase.Adenoviral vector-mediated gene therapy for gliomas: coming of age.Thymidine kinase suicide gene-mediated ganciclovir ablation of autologous gene-modified rhesus hematopoiesis.HSV-TK/GCV cancer suicide gene therapy by a designed recombinant multifunctional vector.Rapamycin enhances adenovirus-mediated cancer imaging and therapy in pre-immunized murine hostsDestruction of tumor vasculature and abated tumor growth upon VEGF blockade is driven by proapoptotic protein Bim in endothelial cells.Stem cells as vectors to deliver HSV/tk gene therapy for malignant gliomasHorizontally acquired genes in early-diverging pathogenic fungi enable the use of host nucleosides and nucleotidesThe role of herpes simplex virus-1 thymidine kinase alanine 168 in substrate specificity.Directed evolution of an orthogonal nucleoside analog kinase via fluorescence-activated cell sorting.Novel application of lentiviral vectors towards treatment of graft-versus-host disease.Enzymes to die for: exploiting nucleotide metabolizing enzymes for cancer gene therapy.Engineering mammalian cells to seek senescence associated secretory phenotypes.Role of Equilibrative Nucleobase Transporter 1/SLC43A3 as a Ganciclovir Transporter in the Induction of Cytotoxic Effect of Ganciclovir in a Suicide Gene Therapy with Herpes Simplex Virus Thymidine Kinase.Conditional Cytotoxic Anti-HIV Gene Therapy for Selectable Cell Modification.An armed, YB-1-dependent oncolytic adenovirus as a candidate for a combinatorial anti-glioma approach of virotherapy, suicide gene therapy and chemotherapeutic treatment.Enzyme/Prodrug Systems for Cancer Gene Therapy.Micro-PET/CT monitoring of herpes thymidine kinase suicide gene therapy in a prostate cancer xenograft: the advantage of a cell-specific transcriptional targeting approach.Direct positive selection for improved nitroreductase variants using SOS triggering of bacteriophage lambda lytic cycle.Pre-clinical development of gene modification of haematopoietic stem cells with chimeric antigen receptors for cancer immunotherapy.Elimination of proliferating cells from CNS grafts using a Ki67 promoter-driven thymidine kinase.Cytoplasmically retargeted HSV1-tk/GFP reporter gene mutants for optimization of noninvasive molecular-genetic imaging.A method for quantification of nucleotides and nucleotide analogues in thymidine kinase assays using lanthanum phosphate coprecipitation.Characterization of an immuno 'stealth' derivative of the herpes simplex virus thymidine-kinase gene.Functional expression of thymidine kinase in human leukaemic and colorectal cells, delivered as EGFP fusion protein by herpesvirus saimiri-based vector.Engineering of a single conserved amino acid residue of herpes simplex virus type 1 thymidine kinase allows a predominant shift from pyrimidine to purine nucleoside phosphorylation.Introduction of Exogenous HSV-TK Suicide Gene Increases Safety of Keratinocyte-Derived Induced Pluripotent Stem Cells by Providing Genetic "Emergency Exit" Switch.Gene therapy with HSV1-sr39TK/GCV exhibits a stronger therapeutic efficacy than HSV1-TK/GCV in rat C6 glioma cells.
P2860
Q27655704-582E72F3-C0BA-4707-93D3-F4D11B4F81FBQ33428576-BA52B4B7-5F2E-4C92-BF5D-40DAA1D38A9DQ33598652-5CACBBD7-46CA-48E9-8EBC-695BBF2DD0FBQ33677054-F6A8AE63-D743-467F-A1E0-EC04C5646858Q33730998-1DA7D857-C0A9-43C6-B28E-C60EE92FEC7DQ33855150-08A1CFA1-DC22-4101-8BA8-3D18077AA03DQ34022048-F25CEDDC-29BA-441E-84A4-3A19547E2FD2Q34295186-82ED74A1-8770-4716-8BBE-221F0C444EF7Q34507776-CC4B7D41-641C-4B97-A739-B894920ED3DCQ34984515-23D70210-2CC1-46D5-B9F6-10D0B580674FQ35102284-40A74E15-EC2C-4377-A689-EF67B91699B4Q36062517-97CDE5A0-68D1-4F7B-9800-475B23C7A8B2Q36821457-D1C573FA-2530-4370-8C0B-70F168550D94Q36944102-21C03DD8-F86C-48CB-B17D-94B5F9314C32Q37273666-D10E3295-D4C5-4D7F-9E22-8497CF6E5937Q37489887-6550D540-B887-4C01-A9BF-F27C00BC5261Q37989984-BE2DB1D1-9709-4A04-A7CD-4CDAC4D0407DQ38654411-1F63335F-E397-4235-969A-87CA3898621FQ38733802-33EA143E-CDA6-4A7C-A10B-93E41211AF29Q38800411-6C52907F-D7B5-4AE7-9D0A-9910413D4631Q38929123-D365D89B-24F8-4015-B22A-A6339739387AQ39064497-F675E2AE-E354-4E13-B8E1-28737144D6CAQ39516198-85A18E8F-B771-479E-B6A9-3B46FBD0281FQ40170852-F0730F2B-C2A5-4B70-AEB3-149059C523F0Q40393182-08F286DC-8BB5-4B24-A432-3A17282AEEE8Q40418970-4148885D-CC14-42D7-902D-E60ECCA8246DQ41589159-F731EC4E-8119-4E62-AF7D-B7C096980EA1Q42585589-4FE1CD0A-2874-489F-98E3-D4D9DD405383Q44061285-6B4B55BD-2FC7-44AC-BC79-7600AAE85468Q44970732-B17A9B2E-BDCE-4D24-8C46-BFE96BFAC1A7Q45416648-F5BA8E57-6D49-43B8-9FB9-3D744020C1F3Q47556660-981A7705-38F8-43F2-BBB3-BE6585388BB8Q51467919-431E298E-468D-4508-99F0-748527E61781
P2860
Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Characterization of herpes sim ...... iclovir or acyclovir activity.
@ast
Characterization of herpes sim ...... iclovir or acyclovir activity.
@en
type
label
Characterization of herpes sim ...... iclovir or acyclovir activity.
@ast
Characterization of herpes sim ...... iclovir or acyclovir activity.
@en
prefLabel
Characterization of herpes sim ...... iclovir or acyclovir activity.
@ast
Characterization of herpes sim ...... iclovir or acyclovir activity.
@en
P2860
P356
P1433
P1476
Characterization of herpes sim ...... iclovir or acyclovir activity.
@en
P2093
Margaret E Black
Mark S Kokoris
P2860
P304
P356
10.1110/PS.2460102
P577
2002-09-01T00:00:00Z